Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N W C J van de Donk,N Kröger,Ute Hegenbart,Paolo Corradini,J F San Miguel,H. Goldschmidt,José Antonio Pérez-Simón,Mark Zijlmans,Reinier Raymakers,Vittorio Montefusco,Francis Ayuk,M. H. J. Van Oers,Arnon Nagler,Leo F. Verdonck,H M Lokhorst +14 more
Reads0
Chats0
TLDR
Donor lymphocyte infusion following non-myeloablative Allo-SCT is a valuable strategy for relapsed or persistent disease and there was a trend towards significance for time between transplantation and DLI, and response.Abstract:
In this retrospective study, we evaluated donor lymphocyte infusions given for relapsed (n=48) or persistent (n=15) myeloma following non-myeloablative allogeneic stem cell transplantation (Allo-SCT). Twenty-four of 63 patients (38.1%) responded: 12 patients (19.0%) with a partial response (PR) and 12 patients (19.0%) with a complete response (CR). Overall survival after donor lymphocyte infusions (DLI) was 23.6 months (1.0-50.7+). Median overall survival for non-responding patients was 23.6 months and has not been reached for the patients responding to DLI. In responders, progression-free survival after DLI was 27.8 months (1.2-46.2+). Patients with a PR had a median progression-free survival of 7.0 months, whereas patients with a CR to DLI had a median progression-free survival of 27.8 months. Major toxicities were acute graft-versus-host disease (GVHD) (38.1%) and chronic GVHD (42.9%). Seven patients (11.1%) died from treatment-related mortality. The only significant prognostic factors for response to DLI were the occurrence of acute and chronic GVHD. There was a trend towards significance for time between transplantation and DLI, and response. Donor lymphocyte infusion following non-myeloablative Allo-SCT is a valuable strategy for relapsed or persistent disease.read more
Citations
More filters
Journal ArticleDOI
Graft-versus-leukemia effects of transplantation and donor lymphocytes
TL;DR: It is learned from adoptive immunotherapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for the effective treatment of leukemia and other malignancies.
Journal ArticleDOI
Multiple myeloma, version 3.2021
Shaji Kumar,Natalie S. Callander,Kehinde Adekola,Larry D. Anderson,Muhamed Baljevic,Erica L. Campagnaro,Jorge J. Castillo,Jason C. Chandler,Caitlin Costello,Yvonne A. Efebera,Matthew Faiman,Alfred L. Garfall,Kelly N. Godby,Jens Hillengass,Leona Holmberg,Myo Htut,Carol Ann Huff,Yubin Kang,Malin Hultcrantz,Sarah Larson,Michaela Liedtke,Thomas Martin,James L. Omel,Kenneth H. Shain,Douglas W. Sborov,Keith Stockerl-Goldstein,Donna M. Weber,Jennifer Keller,Rashmi Kumar +28 more
TL;DR: This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple Myeloma, and newly diagnosed multiple myeloma.
Journal ArticleDOI
International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
Henk M. Lokhorst,Hermann Einsele,David H. Vesole,Benedetto Bruno,Jesús F. San Miguel,José A. Pérez-Simón,Nicolaus Kröger,Philippe Moreau,Gösta Gahrton,Cristina Gasparetto,Sergio Giralt,William I. Bensinger +11 more
TL;DR: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation.
Journal ArticleDOI
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
David L. Porter,Edwin P. Alyea,Joseph H. Antin,Marcos DeLima,Eli Estey,J.H. Frederik Falkenburg,Nancy M. Hardy,Nicolaus Kroeger,Jose F. Leis,John E. Levine,David G. Maloney,Karl S. Peggs,Jacob M. Rowe,Alan S. Wayne,Sergio Giralt,Michael R. Bishop,Koen van Besien +16 more
TL;DR: There is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT, and recommendations are provided for specific areas of research necessary in the treatment of relapsed diseases.
Journal ArticleDOI
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited
Abhinav Deol,Lawrence G. Lum +1 more
TL;DR: The responses in patients with CML are durable whereas durable responses in other diseases are rare, and DLI has taken a backseat given the development of new drugs to treat some hematological diseases.
References
More filters
Journal ArticleDOI
Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 seattle patients
Howard M. Shulman,Keith M. Sullivan,Paul L. Weiden,George B. McDonald,Gary E. Striker,George E. Sale,Robert C. Hackman,Tsoi Ms,Rainer Storb,E. Donnall Thomas +9 more
TL;DR: Three patients had limited chronic GVHD with relatively favorable prognosis characterized by localized skin involvement and/or hepatic disease without chronic aggressive histology, but most patients, however, had extensive disease with a progressive course.
Journal ArticleDOI
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Joan Bladé,Diana Samson,Donna E. Reece,Jane F. Apperley,Bo Björkstrand,Gösta Gahrton,Morie A. Gertz,Sergio Giralt,SUNDARr Jagannath,David H. Vesole +9 more
TL;DR: New criteria for response and progression have been developed as a result of discussions between representatives of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and representatives ofThe Myelomas Working Committee of the Autologousblood and marrow transplant Registry (ABMTR) and the International Bone Marrowtransplant Registry (IBMTR).
Journal ArticleDOI
Bone-marrow transplantation (second of two parts).
Thomas Ed,Rainer Storb,Clift Ra,Alexander Fefer,Johnson L,Paul E. Neiman,Lerner Kg,Glucksberg H,C. D. Buckner +8 more
Journal ArticleDOI
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
David G. Maloney,Arthur J. Molina,Firoozeh Sahebi,Keith Stockerl-Goldstein,Brenda M. Sandmaier,William I. Bensinger,Barry E. Storer,Ute Hegenbart,George Somlo,Thomas R. Chauncey,Benedetto Bruno,Frederick R. Appelbaum,Karl G. Blume,Stephen J. Forman,Peter A. McSweeney,Rainer Storb +15 more
TL;DR: Despite being evaluated in elderly patients with MM, this 2-step approach has reduced the acute toxicities of allogeneic HCT while achieving potent antitumor activities.
Journal ArticleDOI
Graft-versus-leukemia reactions in allogeneic chimeras
Hans-Jochem Kolb,Hans-Jochem Kolb,Christoph Schmid,Christoph Schmid,A. John Barrett,A. John Barrett,Dolores J. Schendel,Dolores J. Schendel +7 more
TL;DR: It is demonstrated that the GVL effect of DLT is most effective in chronic myelogenous leukemia (CML), whereas it is less pronounced in acute leukemia and myeloma, and new approaches for adoptive immune therapy of leukemia, which promise a better prognosis for these patients are being developed.
Related Papers (5)
A comparison of allografting with autografting for newly diagnosed myeloma.
Benedetto Bruno,Marcello Rotta,Francesca Patriarca,Nicola Mordini,Bernardino Allione,Fabrizio Carnevale-Schianca,Luisa Giaccone,Roberto Sorasio,Paola Omedè,Ileana Baldi,Sara Bringhen,Massimo Massaia,Massimo Aglietta,Alessandro Levis,Andrea Gallamini,Renato Fanin,Antonio Palumbo,Rainer Storb,Giovannino Ciccone,Mario Boccadoro +19 more